Literature DB >> 6232374

Effects of nicorandil, a new antianginal agent, and nifedipine on collateral blood flow in a chronic coronary occlusion model.

K A Lamping, D C Warltier, H F Hardman, G J Gross.   

Abstract

The effects of nicorandil and nifedipine on collateral blood flow were compared in anesthetized dogs with a well-developed collateral circulation produced by Ameroid constriction (6-8 weeks) of the left anterior descending (LAD) coronary artery. The radioactive microsphere technique was used to determine myocardial perfusion in the normal left circumflex (LC) region and in the LAD region distal to the Ameroid constrictor. Low and high doses of nicorandil (25 and 50 micrograms/kg/min) or nifedipine (1 and 3 micrograms/kg/min) were infused i.v. to reduce mean arterial and left ventricular systolic pressure approximately 10 and 25 mm Hg, respectively. A low dose of nicorandil had no effect on myocardial perfusion whereas nifedipine increased subepicardial blood flow in both the LC and LAD regions. The high dose of nifedipine further increased both subepicardial and subendocardial perfusion to the LC region and subepicardial blood flow to the LAD region whereas nicorandil had no effect. When aortic blood pressure was returned to control by occluding a snare around the descending thoracic aorta during infusion of the high dose, nicorandil and nifedipine increased subepicardial and subendocardial blood flow to LAD and LC regions. Whereas nicorandil increased flow to both tissue layers equally, nifedipine increased subepicardial perfusion primarily. In summary, nifedipine increased collateral blood flow in a chronic coronary occlusion model despite the presence of systemic hypotension, whereas nicorandil only increased flow when aortic blood pressure was maintained. However, nicorandil increased myocardial blood flow equally across the left ventricular wall, whereas nifedipine primarily increased subepicardial blood flow.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6232374

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Nicorandil-induced changes in the distribution of cardiac output and coronary blood flow in pigs.

Authors:  P D Verdouw; L M Sassen; D J Duncker; I O Schmeets; R J Rensen; P R Saxena
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-09       Impact factor: 3.000

Review 2.  Pharmacology and therapeutic effects of nicorandil.

Authors:  M Kinoshita; K Sakai
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Left ventricular effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs.

Authors:  K Hashimoto; Y Ohbayashi; M Kinoshita
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

Review 4.  Effects of nicorandil on regional perfusion and left ventricular function.

Authors:  M Schlepper; J Thormann; K Berwing; R Strasser; V Mitrovic
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

5.  Antiischemic effects of nicorandil during coronary angioplasty in humans.

Authors:  S Saito; T Mizumura; T Takayama; J Honye; T Fukui; T Kamata; M Moriuchi; K Hibiya; Y Tamura; Y Ozawa
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

6.  Study of the efficacy of nicorandil in patients with ischaemic heart disease using Exercise-T1-201 myocardial tomography.

Authors:  J Yamazaki; H Ohsawa; T Uchi; M Iida; H Nakano; H Hosoi; T Morishita; Y Yabe; N Koyama; H Komatsu
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Nifedipine effects in severe myocardial ischaemia in the dog due to left anterior descending coronary occlusion with left circumflex coronary artery constriction.

Authors:  L Szekeres; E Udvary; A Végh
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

8.  Enhancement of muscle blood cell flux and pO2 by cromakalim (BRL 34915) and other compounds enhancing membrane K+ conductance, but not by Ca2+ antagonists or hydralazine, in an animal model of occlusive arterial disease.

Authors:  D Angerbach; C D Nicholson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-03       Impact factor: 3.000

9.  Nicorandil was an Effective Treatment Option for a Patient with Bland-White-Garland Syndrome.

Authors:  Shun Morishita; Hirofumi Maeba; Kazuya Takehana; Ichiro Shiojima
Journal:  Intern Med       Date:  2017-08-10       Impact factor: 1.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.